BioSpace News Archive

- The success of the procedure unleashes a new era for retrievable interventional cardiac valve technology in China [28-November-2017] HANGZHOU, China, Nov. 28, 2017 /PRNewswire/ -- The first human implantation of the VenusA Plus retrievable valve system was completed successfully at the Second Affiliated Hospital of Zhejiang University School of Medicine (SA

The safety profile of avelumab was consistent with that observed in the overall JAVELIN clinical development program.

Financial details about the transaction were not disclosed.

Q Biomed announced today that Dr. Helen Tager-Flusberg from Boston University has joined its advisory committee for QBM-001, which is being tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders.

Significant Natesto prescription growth continued through October 2017, with prescriptions increasing 17% from the previous month, reaching their highest levels to date.

The company will host a conference call to discuss the results that day at 4:30 p.m. EST (1:30 p.m. PST).

The power of dedicated research, and discovery of new gene mutation variants help develop much-needed treatments.

PhaseRx today announced that the EMA’s Committee for Orphan Medicinal Products has issued a positive opinion recommending orphan medicinal product designation for PRX-ASL, for the treatment of ASLD, PhaseRx’s second drug candidate to treat a urea cycle disorder.

Mr. Cross has over twenty years of experience, with executive leadership roles in both private and public biotechnology companies.

The University of Washington used the Nortis ParVivo system in this study that was published in JCI Insights and highlighted as its cover article.